AZ Wins Chinese Nod for Lagging Bloodthinner Brilinta
Published: Thursday, November 29th 2012
(Fierce) - AstraZeneca ($AZN) nabbed China's approval for its clot-fighter Brilinta, once considered a big fish for the U.K.-based drugmaker. The drug hasn't performed nearly as well as originally hoped, at least so far. Perhaps sales in China, where drug spending is growing faster than in Europe or the U.S., will help jump-start the product.